Antibody-Drug Combination Falls Short in First-Line PD-L1-High Metastatic Lung Cancer Trial
Antibody-Drug Combination Falls Short in First-Line PD-L1-High Metastatic Lung Cancer Trial Bioengineer.org
Онкология
🎗️Лента новостей
🎗️
Онкология
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical CollegeのJie Wang教授は述べた。
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical CollegeのJie Wang教授は述べた。 EurekAlert!
Онкология
Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer
Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer EurekAlert!
Онкология
Студент Ханойского медицинского университета и его неожиданное путешествие в область онкологии.
Студент Ханойского медицинского университета и его неожиданное путешествие в область онкологии. Vietnam.vn
Онкология
Exercise Could Help Cancer Patients on Immunotherapy, But Nobody Is Telling Them How
Exercise Could Help Cancer Patients on Immunotherapy, But Nobody Is Telling Them How Bioengineer.org
🎗️
Онкология
Trial supports MRI surveillance over preventive brain radiation in small-cell lung cancer
Results from the international phase 3 SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small-cell lung cancer (SCLC). The findings support MRI surveillance alone as the…
Онкология
Ivonescimab significantly improves overall survival versus pembrolizumab in advanced lung cancer
Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung…
Онкология
Trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer
Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based…
Онкология
Combination therapy does not meet primary endpoints in first-line PD-L1-high metastatic non-small cell lung cancer
Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of 50% or greater…
Онкология
Tam-Peli extends survival by nearly four months in relapsed small-cell lung cancer
The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC). The findings were…
🎗️
Онкология
Merck, Gilead’s failed Trodelvy lung cancer trial shows better China results
Merck, Gilead’s failed Trodelvy lung cancer trial shows better China results fiercepharma.com
Онкология
Swim Across America RI raises money for cancer research
Swim Across America RI raises money for cancer research WJAR
Онкология
Ученые нашли способ "обойти защиту" рака поджелудочной железы
Ученые нашли способ "обойти защиту" рака поджелудочной железы Report.az
Онкология
Kimryn Rathmell: Welcoming Dr. Liza Makowski to OSU Comprehensive Cancer Center
Kimryn Rathmell: Welcoming Dr. Liza Makowski to OSU Comprehensive Cancer Center oncodaily.com